UPDATE: UBS Upgrades Amgen (AMGN) to Buy; Pipeline Visibility Higher

September 10, 2012 7:38 AM EDT Send to a Friend
Get Alerts AMGN Hot Sheet
Price: $170.17 +1.00%

Rating Summary:
    15 Buy, 13 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 14 | Down: 28 | New: 51
Trade AMGN Now!
Join SI Premium – FREE
(Updated - September 10, 2012 12:22 PM EDT)

UBS upgraded Amgen (NASDAQ: AMGN) from Neutral to Buy. PT raised from $80 to $96.

Analyst, Matthew Roden, said, "Our previous Neutral rating on the industry bellwether had been predicated on an anemic topline growth profile, and a lack of visibility into clear revenue growth drivers in the pipeline. We now take a more constructive outlook ahead of phase 2 data for AMG 145 (lipid-lowering) and AMG 785 (bone health)."

FY13 EPS estimate raised from $6.27 to $6.81.

For an analyst ratings summary and ratings history on Amgen click here. For more ratings news on Amgen click here.

Shares of Amgen closed at $83.96 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst EPS Change, Analyst EPS View, Analyst PT Change, Upgrades

Related Entities

UBS

Add Your Comment